Value appropriation in hepatitis C
Author
Abstract
Suggested Citation
DOI: 10.1007/s10198-021-01409-7
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Jamison Pike & Scott D. Grosse, 2018. "Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 765-778, December.
- Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
- Antonio Blázquez-Pérez & Ramón San Miguel & Javier Mar, 2013. "Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients," PharmacoEconomics, Springer, vol. 31(10), pages 919-931, October.
- Johannesson, Magnus & Karlsson, Goran, 1997. "The friction cost method: A comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 249-255, April.
- Jagpreet Chhatwal & Tianhua He & Maria A. Lopez-Olivo, 2016. "Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals," PharmacoEconomics, Springer, vol. 34(6), pages 551-567, June.
- Peter Lindgren & Bengt Jönsson, 2012. "Cost–effectiveness of statins revisited: lessons learned about the value of innovation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 445-450, August.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Ina Rissanen & Leena Ala-Mursula & Iiro Nerg & Marko Korhonen, 2021. "Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 531-545, June.
- L. M. Peña-Longobardo & J. Oliva-Moreno & C. Fernández-Rodriguez, 2023. "The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1271-1283, November.
- Rakesh Aggarwal & Qiushi Chen & Amit Goel & Nicole Seguy & Razia Pendse & Turgay Ayer & Jagpreet Chhatwal, 2017. "Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-15, May.
- Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
- Beata Gavurova & Miriama Tarhanicova, 2021. "Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption," IJERPH, MDPI, vol. 18(9), pages 1-25, May.
- Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
- Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay, 2005. "Indirect costs of cervical and breast cancers in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 309-313, December.
- Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1997. "Reply to Johanneson's and Karlsson's comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 257-259, April.
- Błażej Łyszczarz & Karolina Sowa, 2022. "Production losses due to mortality associated with modifiable health risk factors in Poland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 33-45, February.
- Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
- Guillem López-Casasnovas & José Luis Pinto Prades, 2022. "QALY Maximization and the Social Optimum," Hacienda Pública Española / Review of Public Economics, IEF, vol. 242(3), pages 111-127, September.
- Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
- Paul Hanly & Marta Ortega Ortega & Alison Pearce & Marianna Camargo Cancela & Isabelle Soerjomataram & Linda Sharp, 2023. "Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries," PharmacoEconomics, Springer, vol. 41(9), pages 1093-1101, September.
- Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
- Ugne Sabale & Mattias Ekman & Daniel Thunström & Claire Telford & Christopher Livings, 2017. "Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden," PharmacoEconomics - Open, Springer, vol. 1(4), pages 279-290, December.
- Björn Sund & Mikael Svensson, 2018. "Estimating a constant WTP for a QALY—a mission impossible?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 871-880, July.
- S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2018.
"Measuring the end-of-life premium in cancer using individual ex ante willingness to pay,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 807-820, July.
- Olofsson , Sara & Gerdtham, Ulf-G. & Hultkrantz, Lars & Persson, Ulf, 2016. "Measuring the End of Life Premium in Cancer using Individual ex ante Willingness to Pay," Working Papers 2016:23, Lund University, Department of Economics.
- Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 55-64, July.
More about this item
Keywords
Hepatitis C; Consumer surplus; Producer surplus; Pharmaceutical reimbursement; Cost-effectiveness;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:23:y:2022:i:6:d:10.1007_s10198-021-01409-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.